Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureZhaojun Pang, Yifu Liu, HanYang, RuiWang, Xuliang Wang, Shouchun Peng, Xueren Li, Shupeng Sun, Xin Mu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Mechanisms of natural killer cell-mediated cellular cytotoxicity
10.1002/jlb.mr0718-269r · 2019
Perforin and granzymes: function, dysfunction and human pathology
10.1038/nri3839 · 2015
Natural killer cell-based strategies for immunotherapy of cancer
10.1016/bs.apcsb.2022.02.001 · 2022
CRISPR screen to identify factors that render tumor cells sensitive or resistant to killing by NK cells
10.1007/978-1-0716-2160-8_19 · 2022
Unifying concepts of MHC-dependent natural killer cell education
10.1016/j.it.2011.06.001 · 2011
CRISPR enabled precision oncology: from gene editing to tumor microenvironment remodeling
2025
A flow cytometry-based whole blood natural killer cell cytotoxicity assay using overnight cytokine activation
10.3389/fimmu.2020.01851 · 2020
CD107a degranulation assay to evaluate immune cell antitumor activity
10.1007/978-1-4939-8885-3_7 · 2019
iRGD tumor penetrating peptide-modified NK cells exhibit enhanced tumor immune infiltration ability and anti-tumor efficacy
10.2174/0109298665348639250115113650 · 2025
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
10.3324/haematol.2013.103085 · 2014
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
10.1080/19420862.2021.1950264 · 2021
NKG2D and its ligands in cancer
10.1016/j.coi.2018.02.004 · 2018
NKG2D ligands-critical targets for cancer immune escape and therapy
10.3389/fimmu.2018.02040 · 2018
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
10.1038/nature03884 · 2005
The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells
10.3389/fimmu.2013.00508 · 2014
Tumor-associated MICA is shed by ADAM proteases
10.1158/0008-5472.can-07-6768 · 2008
Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes
10.1158/0008-5472.can-09-1688 · 2010
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy
10.1186/s13046-021-02068-5 · 2021
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines
10.1007/s00262-009-0682-y · 2009
DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses
10.1093/intimm/dxab085 · 2021
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
10.1038/s41423-019-0206-4 · 2019
HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition
10.1093/intimm/13.2.193 · 2001
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
10.1172/jci0215564 · 2002
Association of HLA class I and class II antigen expression and mortality in uveal melanoma
2001
The NKG2A-HLA-E Axis as a novel checkpoint in the tumor microenvironment
10.1158/1078-0432.ccr-19-2095 · 2020
Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer
10.3390/vaccines10121993 · 2022
Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors
10.2147/itt.s61498 · 2015
NK cell metabolism and tumor microenvironment
10.3389/fimmu.2019.02278 · 2019
Hepatic tumor microenvironments and effects on NK cell phenotype and function
10.3390/ijms20174131 · 2019
Regulatory effects of oncogenes and tumor suppressor genes on tumor immune microenvironment
10.3724/j.pibb.2025.0317 · 2025
Mechanisms of resistance to NK cell immunotherapy
10.3390/cancers12040893 · 2020
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
10.1038/s41422-020-0355-0 · 2020
The lytic NK cell immunological synapse and sequential steps in its formation
10.1007/978-0-387-72005-0_23 · 2007
The central role of the cytoskeleton in mechanisms and functions of the NK cell immune synapse
10.1111/imr.12107 · 2013
Cytotoxic immunological synapses
10.1111/j.0105-2896.2010.00904.x · 2010
Navigating barriers: the challenge of directed secretion at the natural killer cell lytic immunological synapse
10.1007/s10875-010-9372-y · 2010
Activation of lymphocyte cytolytic machinery: where are we?
10.3389/fimmu.2013.00390 · 2013
Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization
10.4049/jimmunol.1000761 · 2010
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
10.1136/jitc-2023-008155 · 2024
TIGIT affects CAR NK-cell effector function in the solid tumor microenvironment by modulating immune synapse strength
10.1158/2326-6066.cir-24-0919 · 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
10.1016/s0140-6736(24)02462-0 · doi-reference
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
10.1038/s41591-025-03640-8 · doi-reference
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
10.1080/10428194.2022.2095623 · doi-reference
Bempegaldesleukin plus Nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results
10.1200/jco.23.00172 · doi-reference
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
10.1080/14653240802301872 · doi-reference
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
10.1158/1078-0432.ccr-11-1347 · doi-reference
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study
10.1016/s1470-2045(21)00216-3 · doi-reference
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial
10.1016/s1470-2045(21)00342-9 · doi-reference
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
10.1182/blood-2011-06-360552 · doi-reference
INTERLINK-1: a phase III, randomized, placebo-controlled study of Monalizumab plus Cetuximab in recurrent/metastatic head and neck squamous cell carcinoma
10.1158/1078-0432.ccr-25-0073 · doi-reference
Randomized phase 2 trial of Lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial
10.1182/blood.v130.suppl_1.889.889 · doi-reference
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
10.1136/jitc-2020-002193 · doi-reference
IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion
10.1158/1078-0432.ccr-18-3468 · doi-reference
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
10.1007/s10637-017-0536-y · doi-reference
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer
10.1200/jco.2009.25.4847 · doi-reference
First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors
10.1158/1078-0432.ccr-24-1991 · doi-reference
Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and Hyporesponsiveness of NK cells in patients with myeloma
10.1158/1078-0432.ccr-16-1108 · doi-reference
Beyond PD-1/PD-L1: new immune checkpoints and therapeutic combinations in cancer immunotherapy
10.1002/mdb2.70018 · doi-reference
Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand
10.1073/pnas.1300140110 · doi-reference
Measuring trogocytosis between ovarian tumor and natural killer cells
10.1016/j.xpro.2022.101425 · doi-reference
C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer
10.1038/s41467-024-54355-2 · doi-reference
The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity
10.1002/ijc.34389 · doi-reference
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
10.1038/s41392-020-00348-8 · doi-reference
NK cell exhaustion in the tumor microenvironment
10.3389/fimmu.2023.1303605 · doi-reference
Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells
10.3389/fimmu.2018.02517 · doi-reference
Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy
10.1186/s12967-024-05033-w · doi-reference
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
10.1083/jcb.201712085 · doi-reference
NK cell detachment from target cells is regulated by successful cytotoxicity and influences cytokine production
10.1038/s41423-019-0277-2 · doi-reference
Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time
10.1084/jem.20140964 · doi-reference
Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells
10.1182/blood-2015-03-632273 · doi-reference
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
10.1038/s41467-019-08384-x · doi-reference
Lytic granule exocytosis at immune synapses: lessons from neuronal synapses
10.3389/fimmu.2023.1177670 · doi-reference
Locked and loaded: mechanisms regulating natural killer cell lytic granule biogenesis and release
10.3389/fimmu.2022.871106 · doi-reference
The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity
10.1016/j.celrep.2024.115156 · doi-reference
NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing
10.1084/jem.20181454 · doi-reference
Single-cell profiling reveals functional heterogeneity and serial killing in human peripheral and ex vivo-generated CD34+ progenitor-derived natural killer cells
10.1002/adbi.202200207 · doi-reference
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
10.1016/j.cell.2022.03.030 · doi-reference
Bcl-2 Antiapoptotic family proteins and chemoresistance in cancer
10.1016/bs.acr.2017.11.001 · doi-reference
Targeting BCL-2 regulated apoptosis in cancer
10.1098/rsob.180002 · doi-reference
Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway
10.1074/jbc.m009038200 · doi-reference